Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

25.54
-0.1300-0.51%
Post-market: 25.700.1600+0.63%19:57 EDT
Volume:592.93K
Turnover:15.22M
Market Cap:1.82B
PE:-8.20
High:26.15
Open:25.73
Low:25.29
Close:25.67
52wk High:94.90
52wk Low:25.09
Shares:71.31M
Float Shares:55.46M
Volume Ratio:0.42
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1128
EPS(LYR):-2.3852
ROE:-20.21%
ROA:-14.95%
PB:1.34
PE(LYR):-10.71

Loading ...

Structure Therapeutics on Track for Lowest Close Since September 2025

Dow Jones
·
Yesterday

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell
·
Oct 01

Structure Therapeutics CMO Blas Coll Crespo Disposes of USD 124,008 Common Shares

Reuters
·
Sep 23

Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market

Bellwether Stocks Movement
·
Sep 15

AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales

Options & Short Sell
·
Sep 14

GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market

Options & Short Sell
·
Sep 14

Structure weakness ‘disconnected’ from underlying data, says Jefferies

TIPRANKS
·
Sep 09

Structure Falls as Investors Await More Obesity Trial Data, Says Jefferies

Reuters
·
Sep 09

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Sep 09

Structure obesity portfolio updates ‘encouraging,’ says Clear Street

TIPRANKS
·
Sep 09

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08

Structure Therapeutics Releases Amylin and GLP-1 Program Presentation

Reuters
·
Sep 08

Structure Therapeutics Reports Phase 1/2a Data Showing 3.3% Weight Loss for Oral Amylin Agonist ACCG-2671

Reuters
·
Sep 08

Structure Therapeutics - Aleniglipron Demonstrates up to 16.2% Body Weight Reduction at 72 Weeks in Access Ole Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Accg-2671 Demonstrates About 6-Day Half-Life, no Serious Adverse Events, 3.3% Body Weight Loss in Phase 1/2a Sad Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Additional Clinical Data for Aleniglipron Expected in Q4 2026

THOMSON REUTERS
·
Sep 08

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and Glp-1 Programs for Chronic Weight Management

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - First Participants Dosed with Accg-2671 in 12-Week Mad Phase 1/2a Trial; Topline Data Expected 1H 2027

THOMSON REUTERS
·
Sep 08

Structure Therapeutics Management Joins Three September Healthcare Investor Conferences

Reuters
·
Sep 03

Structure Therapeutics CSO Lin Xichen Reports Disposal of Common Shares Worth $275,830.34

Reuters
·
Sep 03